Journal of Multiple Sclerosis and Neuroimmunology

Search

Page Path

HOME
Search

Case Report

Severe Neutropenia Following Rituximab Treatment in Patients with Multiple Sclerosis: Ki Hoon Kim, Su-Hyun Kim, Jae-Won Hyun, Ho Jin Kim; J Mult Scler Neuroimmunol. 2024;15(1):31-34. Published online June 30, 2024; DOI: https://doi.org/10.59578/jmsni.2024.15.1.31; Full text PubReader ePub PDF

Review Article

Rituximab Treatment for Neuroimmunologic Disorders: Ilhan Yoo; J Mult Scler Neuroimmunol. 2023;14(1):44-50. Published online June 30, 2023; DOI: https://doi.org/10.59578/jmsni.2023.14.1.44; Full text PubReader ePub PDF

Review Article

Monoclonal Antibody Therapies for Neuromyelitis Optica Spectrum Disorder: Woojun Kim; J Mult Scler Neuroimmunol. 2023;14(1):15-23. Published online June 30, 2023; DOI: https://doi.org/10.59578/jmsni.2023.14.1.15; Full text PubReader ePub PDF

Case Report

Favorable Response to Rituximab in a Patient with Recurrent Primary Angiitis of the Central Nervous System: A Case Report and Literature Review: Tae Young Kim, Yong Jin Kim, Min Kim, Jae Hyun Jeon, Hyun-Mi Park, Dong Hoon Shin, Jiwon Yang; J Mult Scler Neuroimmunol. 2022;13(2):30-34. Published online December 31, 2022; PDF

Case Report

Successful Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy with Rituximab: Dayoung Kim, Kyomin Choi, Jeeyoung Oh; J Mult Scler Neuroimmunol. 2021;12(2):39-42. Published online December 1, 2021; PDF

Case Report

Delayed Hepatitis B Reactivation after Repeated Rituximab Treatments for Neuromyelitis Optica Spectrum Disorder: Hyesun Lee, Euihyun Sung, Wonjae Sung, Seung Hyun Kim; J Mult Scler Neuroimmunol. 2021;12(2):35-38. Published online December 1, 2021; PDF

Case Report

Steroid-Unresponsive Immune-Mediated Necrotizing Myopathy Successfully Treated with Rituximab: Jong-Su Kim, SeonDeuk Kim, Woohee Ju, Soo Hyun Park, Je-Young Shin, Jung-Joon Sung, Seok-Jin Choi; J Mult Scler Neuroimmunol. 2021;12(1):1-5. Published online January 1, 2021; PDF

Case Report

Cost Effectiveness of First-Line Rituximab in Koreans with Neuromyelitis Optica Spectrum Disorder: Jae-Won Hyun, Hyunmin Jang, Jeongmi Park, Min Young Lee, Su-Hyun Kim, Ho Jin Kim; J Mult Scler Neuroimmunol. 2020;11(2):53-58. Published online December 1, 2020; PDF

Review Article

Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder: Su-Hyun Kim, Jae-Won Hyun, Ho Jin Kim; J Mult Scler Neuroimmunol. 2017;8(1):1-8. Published online March 1, 2017; PDF

Case Report

Successful Treatment of Neuromyelitis Optica with Rituximab: Hyun Du Noh, Min Su Park; J Mult Scler Neuroimmunol. 2010;1(2):59-63. Published online September 1, 2010; PDF

Volume 15, No. 1

Journal of Multiple
Sclerosis and
Neuroimmunology

Print ISSN: 2733-8290
Online ISSN: 2951-2972

MOST VIEWED MOST CITED

6,007	Understanding MRI Features of Multiple Sclerosis: Based on the 2017 McDonald Criteria
2,661	Rituximab Treatment for Neuroimmunologic Disorders
2,351	National Consensus Guidance for the Diagnosis and Management of Adult Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
2,324	Multiple Sclerosis in Korea: A Hospital-Based, Multicenter, Epidemiological Study
2,215	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review

Cited By
2

Multiple Sclerosis in Korea: A Hospital-Based, Multicenter, Epidemiological Study

Editorial Office: Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine 102, Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-3153 E-mail: icandr@cau.ac.kr

Copyright © 2024 by Korean Society of Neuroimmunology.